258 related articles for article (PubMed ID: 32404512)
1. Can Unconventional Immunomodulatory Agents Help Alleviate COVID-19 Symptoms and Severity?
Mamber SW; Krakowka S; Osborn J; Saberski L; Rhodes RG; Dahlberg AE; Pond-Tor S; Fitzgerald K; Wright N; Beseme S; McMichael J
mSphere; 2020 May; 5(3):. PubMed ID: 32404512
[TBL] [Abstract][Full Text] [Related]
2. [Repurposing of chlorpromazine in COVID-19 treatment: the reCoVery study].
Plaze M; Attali D; Petit AC; Blatzer M; Simon-Loriere E; Vinckier F; Cachia A; Chrétien F; Gaillard R
Encephale; 2020 Jun; 46(3S):S35-S39. PubMed ID: 32387014
[TBL] [Abstract][Full Text] [Related]
3. Immunomodulatory Drugs in the Management of SARS-CoV-2.
Burrage DR; Koushesh S; Sofat N
Front Immunol; 2020; 11():1844. PubMed ID: 32903555
[TBL] [Abstract][Full Text] [Related]
4. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
[TBL] [Abstract][Full Text] [Related]
5. Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past.
Shah VK; Firmal P; Alam A; Ganguly D; Chattopadhyay S
Front Immunol; 2020; 11():1949. PubMed ID: 32849654
[TBL] [Abstract][Full Text] [Related]
6. Cholesterol 25-Hydroxylase inhibits SARS-CoV-2 and other coronaviruses by depleting membrane cholesterol.
Wang S; Li W; Hui H; Tiwari SK; Zhang Q; Croker BA; Rawlings S; Smith D; Carlin AF; Rana TM
EMBO J; 2020 Nov; 39(21):e106057. PubMed ID: 32944968
[TBL] [Abstract][Full Text] [Related]
7. Hazards of the Cytokine Storm and Cytokine-Targeted Therapy in Patients With COVID-19: Review.
Quirch M; Lee J; Rehman S
J Med Internet Res; 2020 Aug; 22(8):e20193. PubMed ID: 32707537
[TBL] [Abstract][Full Text] [Related]
8. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
9. [Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Should we target the virus, the cell or the disease?].
Nisole S; Saulnier A; Gatignol A
Virologie (Montrouge); 2020 Jun; 24(3):135-141. PubMed ID: 32648548
[No Abstract] [Full Text] [Related]
10. Advances in the use of chloroquine and hydroxychloroquine for the treatment of COVID-19.
Sun J; Chen Y; Fan X; Wang X; Han Q; Liu Z
Postgrad Med; 2020 Sep; 132(7):604-613. PubMed ID: 32496926
[TBL] [Abstract][Full Text] [Related]
11. The role of Interleukin 6 inhibitors in therapy of severe COVID-19.
Nasonov E; Samsonov M
Biomed Pharmacother; 2020 Nov; 131():110698. PubMed ID: 32920514
[TBL] [Abstract][Full Text] [Related]
12. Approaching coronavirus disease 2019: Mechanisms of action of repurposed drugs with potential activity against SARS-CoV-2.
Lisi L; Lacal PM; Barbaccia ML; Graziani G
Biochem Pharmacol; 2020 Oct; 180():114169. PubMed ID: 32710969
[TBL] [Abstract][Full Text] [Related]
13. Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus.
Martinez MA
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32152082
[TBL] [Abstract][Full Text] [Related]
14. The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19.
Perricone C; Triggianese P; Bartoloni E; Cafaro G; Bonifacio AF; Bursi R; Perricone R; Gerli R
J Autoimmun; 2020 Jul; 111():102468. PubMed ID: 32317220
[TBL] [Abstract][Full Text] [Related]
15. COVID-19 Drug Discovery Using Intensive Approaches.
Asai A; Konno M; Ozaki M; Otsuka C; Vecchione A; Arai T; Kitagawa T; Ofusa K; Yabumoto M; Hirotsu T; Taniguchi M; Eguchi H; Doki Y; Ishii H
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32325767
[TBL] [Abstract][Full Text] [Related]
16. Immunomodulatory and Antiviral Activity of Metformin and Its Potential Implications in Treating Coronavirus Disease 2019 and Lung Injury.
Chen X; Guo H; Qiu L; Zhang C; Deng Q; Leng Q
Front Immunol; 2020; 11():2056. PubMed ID: 32973814
[TBL] [Abstract][Full Text] [Related]
17. Immune Modulation as a Therapeutic Option During the SARS-CoV-2 Outbreak: The Case for Antimalarial Aminoquinolines.
Vitte J; Michel M; Mezouar S; Diallo AB; Boumaza A; Mege JL; Desnues B
Front Immunol; 2020; 11():2159. PubMed ID: 32983179
[TBL] [Abstract][Full Text] [Related]
18. Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents.
Khadke S; Ahmed N; Ahmed N; Ratts R; Raju S; Gallogly M; de Lima M; Sohail MR
Virol J; 2020 Oct; 17(1):154. PubMed ID: 33059711
[TBL] [Abstract][Full Text] [Related]
19. Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies.
Zhao M
Int J Antimicrob Agents; 2020 Jun; 55(6):105982. PubMed ID: 32305588
[TBL] [Abstract][Full Text] [Related]
20. Prevention and treatment of COVID-19 disease by controlled modulation of innate immunity.
Schijns V; Lavelle EC
Eur J Immunol; 2020 Jul; 50(7):932-938. PubMed ID: 32438473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
